100 Participants Needed

Acute Intermittent Hypoxia for Spinal Cord Injury

Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: University of Colorado, Boulder
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

The goal of this study is to clarify mechanisms of acute intermittent hypoxia and to examine the effect on lower limb function in persons with chronic, incomplete spinal cord injury.

Will I have to stop taking my current medications?

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What data supports the effectiveness of the treatment Acute Intermittent Hypoxia for Spinal Cord Injury?

Research shows that Acute Intermittent Hypoxia (AIH) can improve motor function in individuals with chronic spinal cord injury by enhancing spinal plasticity, which is the ability of the spinal cord to adapt and recover. Studies in animal models and humans have demonstrated that AIH can lead to sustained improvements in both respiratory and non-respiratory motor functions.12345

Is acute intermittent hypoxia generally safe for humans?

Research on acute intermittent hypoxia (AIH) in humans, particularly those with spinal cord injuries, suggests it is generally safe, though individual responses can vary. Studies have shown AIH can enhance motor function and breathing, but more research is needed to fully understand its safety and effectiveness.12678

How does the treatment Acute Intermittent Hypoxia differ from other treatments for spinal cord injury?

Acute Intermittent Hypoxia (AIH) is unique because it involves brief, repeated exposures to low oxygen levels, which can trigger neuroplasticity (the brain's ability to reorganize itself) and improve breathing function in people with spinal cord injuries. Unlike traditional exercise-based rehabilitation, AIH is a time-efficient and potentially more accessible approach to enhance physical function and respiratory capacity.167910

Eligibility Criteria

This trial is for people aged 18-75 with chronic, incomplete spinal cord injuries between C2 and L5 levels or non-traumatic disorders like MS. They must be medically stable, over a year post-injury, and able to take one step unaided or with devices. Excluded are those with recent concussions, metal head implants/pacemakers, needle aversion, pregnancy plans, severe illnesses/pain, cardiovascular issues, untreated musculoskeletal problems or mental health conditions.

Inclusion Criteria

Medically stable with medical clearance from physician to participate
My spinal cord injury allows some movement and is between my neck and lower back.
My spinal cord injury is classified as AIS A-D or is due to a non-traumatic disorder.
See 2 more

Exclusion Criteria

Concussion within the last six months
Metal implants in the head, or pacemaker
Aversion to needles
See 9 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2 weeks
1 visit (in-person)

Baseline Assessment

Baseline measurements including MRI, 6-Minute Walk Test, and 10-Meter Walk Test are conducted

1 week
1 visit (in-person)

Treatment

Participants undergo 4 consecutive days of acute intermittent hypoxia or normoxia exposure

1 week
4 visits (in-person)

Follow-up

Participants are monitored for changes in biomarkers and functional tests after treatment

1 week
1 visit (in-person)

Treatment Details

Interventions

  • Acute Intermittent Hypoxia
Trial Overview The study investigates the effects of Acute Intermittent Hypoxia (AIH) on serum blood proteins and lower limb function in individuals with incomplete spinal cord injury. It aims to understand how AIH influences recovery mechanisms and physical capabilities in affected limbs.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: AIH GroupExperimental Treatment1 Intervention
Participants will be exposed to 4 consecutive days of acute intermittent hypoxia (AIH): 15, 1.5 min episodes at 9% O2 alternating with 21% O2 at 1 min intervals.
Group II: SHAM GroupActive Control1 Intervention
Participants will be exposed to 4 consecutive days of normoxia: 15, 1.5 min episodes at 21% O2 alternating with 21% O2 at 1 min intervals.

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Colorado, Boulder

Lead Sponsor

Trials
128
Recruited
29,600+

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Collaborator

Trials
2,103
Recruited
2,760,000+

University of Colorado, Denver

Collaborator

Trials
1,842
Recruited
3,028,000+

Findings from Research

Acute intermittent hypoxia has shown promise as a therapeutic strategy to improve respiratory function in individuals with cervical spinal cord injuries, based on studies that demonstrate its potential to induce neuroplasticity and functional recovery.
Research in animal models has laid the groundwork for exploring the effects of acute intermittent hypoxia in human clinical studies, highlighting its potential to restore breathing function after spinal cord injury.
Intermittent hypoxia and respiratory recovery in pre-clinical rodent models of incomplete cervical spinal cord injury.Gonzalez-Rothi, EJ., Lee, KZ.[2021]
Acute intermittent hypoxia (AIH) significantly improved lower extremity muscle strength in adults with chronic incomplete spinal cord injury, with torque increasing by approximately 20% at 30 minutes and 30% at 60 minutes post-AIH.
Pretreatment with ibuprofen did not enhance the effects of AIH on muscle strength, indicating that while AIH is effective for improving leg strength, systemic inflammation management with ibuprofen may not be necessary for its benefits.
Effect of acute intermittent hypoxia on motor function in individuals with chronic spinal cord injury following ibuprofen pretreatment: A pilot study.Lynch, M., Duffell, L., Sandhu, M., et al.[2018]
Individuals with cervical spinal cord injury (SCI) showed a significantly higher short-term hypoxic ventilatory response (HVR) during acute intermittent hypoxia (AIH) compared to those with thoracic SCI, indicating a potentially different respiratory response mechanism in cervical SCI patients.
Despite the increased short-term HVR, there was no evidence of long-term ventilatory facilitation following AIH in either cervical or thoracic SCI groups, suggesting that while acute responses may differ, long-term adaptations in ventilation are not observed.
Tetraplegia is associated with increased hypoxic ventilatory response during nonrapid eye movement sleep.Vaughan, S., Sankari, A., Carroll, S., et al.[2023]

References

Intermittent hypoxia and respiratory recovery in pre-clinical rodent models of incomplete cervical spinal cord injury. [2021]
Effect of acute intermittent hypoxia on motor function in individuals with chronic spinal cord injury following ibuprofen pretreatment: A pilot study. [2018]
Tetraplegia is associated with increased hypoxic ventilatory response during nonrapid eye movement sleep. [2023]
Therapeutic acute intermittent hypoxia: A translational roadmap for spinal cord injury and neuromuscular disease. [2023]
Prolonged acute intermittent hypoxia improves forelimb reach-to-grasp function in a rat model of chronic cervical spinal cord injury. [2021]
Tetraplegia is associated with enhanced peripheral chemoreflex sensitivity and ventilatory long-term facilitation. [2022]
APOE4, Age & Sex Regulate Respiratory Plasticity Elicited By Acute Intermittent Hypercapnic-Hypoxia. [2023]
APOE4, Age, and Sex Regulate Respiratory Plasticity Elicited by Acute Intermittent Hypercapnic-Hypoxia. [2023]
Single-session effects of acute intermittent hypoxia on breathing function after human spinal cord injury. [2022]
10.United Statespubmed.ncbi.nlm.nih.gov
Efficacy of Acute Intermittent Hypoxia on Physical Function and Health Status in Humans with Spinal Cord Injury: A Brief Review. [2018]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security